ESMO 2025 preview – Astellas's third Claudin18.2 shot
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
Astra and J&J tussle over first-line lung
The companies clash over survival curve similarities – and differences.
Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Arvinas and Pfizer turn away from Ibrance
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
Biohaven aims to become an oncology fast follower
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
Regeneron’s fianlimab lung test approaches
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
J&J ramps up its bladder cancer battle
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
ESMO 2024 – Astellas defends its degrader
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
